Literature DB >> 36273166

Health status and associated factors of middle-aged and older adult cancer survivors in India: results from the Longitudinal Ageing Study in India.

Aravinda Meera Guntupalli1, Y Selvamani2, Sara J Maclennan3, T R Dilip4.   

Abstract

BACKGROUND: The number of persons who have survived cancer has been increasing in India as elsewhere due to advances in detection and treatment of this disease. However, evidence on the standardised number of cancer survivors, their characteristics and their complex health challenges on a national level does not exist due to data limitations. This study, therefore, examines the profile of cancer survivors and their health status using the recently released Longitudinal Ageing Study in India (LASI) survey data.
METHODS: LASI wave 1 is a cross-sectional nationally representative survey of 65,562 middle and older adults aged 45 and above. We first calculated the socioeconomic, demographic and geographical characteristics of cancer survivors (per 100,000 population). We later estimated the adjusted odds of poor health, sleep problems, depressive symptoms, activities of living limitations (ADL and IADL), and hospitalisation of cancer survivors using multivariable logistic regression analysis.
RESULTS: According to LASI estimates, there were 2.1 million cancer survivors in India (95% CI 1.8 million to 2.6 million) in 2017-18. Overall, 440 cancer survivors have been identified in this study, with considerable state variations. The number of cancer survivors per 1,00,000 population was relatively more in non-indigenous groups, people with a history of cancer in their families, those who worked earlier but currently not working and those in the richest quintile categories. As compared to those who never had cancer, the cancer survivors are at higher risk of hospitalisation (adjusted odds ratio (aOR) = 2.61 CI 1.86, 3.67), poor self-rated health (aOR = 3.77, CI 2.55, 5.54), depressive symptoms (aOR = 1.53, CI 1.41, 2.05) and sleep problems (aOR = 2.29, CI 1.50, 3.47). They also reported higher ADL (aOR = 1.61, CI 1.11, 2.34) and IADL (aOR = 1.49, CI 1.07, 2.07) limitations. Cancer survivors who had their cancer diagnosis in the past 2 years or a cancer-related treatment in the past 2 years have significantly higher odds of poor health status than middle-aged and older adults without a cancer history.
CONCLUSION: Middle-aged and older cancer survivors, particularly those who underwent cancer diagnosis or treatment in the past 2 years, are at a significantly higher risk of experiencing poor self-reported health and other health challenges, suggesting the need for an integrated healthcare approach.
© 2022. The Author(s).

Entities:  

Keywords:  ADL and IADL limitations; Cancer survivor; General health; India; Mental health; Middle-aged and older adults

Year:  2022        PMID: 36273166     DOI: 10.1186/s12885-022-10111-7

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.638


  11 in total

Review 1.  Global geriatric oncology: Achievements and challenges.

Authors:  Enrique Soto-Perez-de-Celis; Nienke A de Glas; Tina Hsu; Ravindran Kanesvaran; Christopher Steer; Ana Patricia Navarrete-Reyes; Nicolo Matteo Luca Battisti; Yanin Chavarri-Guerra; Anita O'Donovan; Jose Alberto Avila-Funes; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2017-06-20       Impact factor: 3.599

2.  Family history of cancer and the risk of cancer: a network of case-control studies.

Authors:  F Turati; V Edefonti; C Bosetti; M Ferraroni; M Malvezzi; S Franceschi; R Talamini; M Montella; F Levi; L Dal Maso; D Serraino; J Polesel; E Negri; A Decarli; C La Vecchia
Journal:  Ann Oncol       Date:  2013-07-24       Impact factor: 32.976

Review 3.  Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologists.

Authors:  Marie Lange; Olivier Rigal; Bénédicte Clarisse; Bénédicte Giffard; Emmanuel Sevin; Marie Barillet; Francis Eustache; Florence Joly
Journal:  Cancer Treat Rev       Date:  2014-03-20       Impact factor: 12.111

4.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 5.  Cancer in the older Indian population: Understanding the current context in an emerging economy.

Authors:  Suzanne Nethan; Meena Cherian; Etienne Brain; Atreyi Ganguli; Fikru Tullu; Najia Musolino; Roopa Hariprasad; Richard Sullivan; Ravi Mehrotra
Journal:  J Geriatr Oncol       Date:  2021-11-11       Impact factor: 3.599

6.  Factor structure of the CES-D scale among older adults in Chennai, India.

Authors:  Srinivasan Chokkanathan; Jayashree Mohanty
Journal:  Aging Ment Health       Date:  2013-01-17       Impact factor: 3.658

7.  High frequency of young age rectal cancer in a tertiary care centre of southern Assam, North East India.

Authors:  Ruhina Shirin Laskar; Fazlur Rahman Talukdar; Rosy Mondal; Ravi Kannan; Sankar Kumar Ghosh
Journal:  Indian J Med Res       Date:  2014-02       Impact factor: 2.375

8.  The impact of a cancer diagnosis on health and well-being: a prospective, population-based study.

Authors:  Kate Williams; Sarah E Jackson; Rebecca J Beeken; Andrew Steptoe; Jane Wardle
Journal:  Psychooncology       Date:  2015-10-01       Impact factor: 3.894

9.  Associations between breast cancer survivorship and adverse mental health outcomes: A matched population-based cohort study in the United Kingdom.

Authors:  Helena Carreira; Rachael Williams; Garth Funston; Susannah Stanway; Krishnan Bhaskaran
Journal:  PLoS Med       Date:  2021-01-07       Impact factor: 11.069

10.  Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050.

Authors:  Sophie Pilleron; Enrique Soto-Perez-de-Celis; Jerome Vignat; Jacques Ferlay; Isabelle Soerjomataram; Freddie Bray; Diana Sarfati
Journal:  Int J Cancer       Date:  2020-08-17       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.